Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial., PMID:40473449
Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies., PMID:40436467
An evaluation of recaticimab for the treatment of hypercholesterolemia., PMID:40380894
Engineering an alkaline-stable protein A through rational design strategies., PMID:40367905
Lipoprotein(a) Measurement in Lipoprotein Apheresis: Time to Change?, PMID:40181783
Tafolecimab, a Third Monoclonal Antibody for PCSK9 as the Novel Lipid-Lowering Drug Around the World: A Narrative Review., PMID:40167967
Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer., PMID:40155220
Development of a fully automated latex-enhanced immunoturbidimetric method for quantitative serum Lp(a) measurement., PMID:40045089
Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial., PMID:40001082
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects., PMID:39928714
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials., PMID:39877671
Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches., PMID:39781530
Implementation of new Westgard rules suggested by the Westgard Advisor software for five immunological parameters., PMID:39703760
An up-to-date review of emerging biologic therapies for hypercholesterolemia., PMID:39668448
Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin., PMID:39647781
The path of GPR87: from a P2Y-like receptor to its role in cancer progression., PMID:39641798
Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab., PMID:39561225
Laboratory parameters-based logistic regression models for rapid screening of thyroid nodules., PMID:39544979
Prevention and alleviation of allergic rhinitis by oral administration of Lacticaseibacillus paracasei GOLDGUT-Lpc969., PMID:39403377
Novel Targets and Strategies Addressing Residual Cardiovascular Risk in Post-acute Coronary Syndromes Patients., PMID:39385797
The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report., PMID:39342791
Biomarker-enhanced cardiovascular risk prediction in patients with cancer: a prospective cohort study., PMID:39223063
New promises and challenges in the treatment of advanced non-small-cell lung cancer., PMID:39121882
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study., PMID:39054476
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention., PMID:38970537
Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study., PMID:38929525
[Distribution and influencing factors of lipoprotein (a) levels in non-arteriosclerotic cardiovascular disease population in China]., PMID:38889976
Atherothrombotic Risk Factors in Patients With Rheumatoid Arthritis., PMID:38846255
Lysophosphatidic acid promotes ESCC progression by increasing the level of CCL2 secreted by esophageal epithelial cells., PMID:38837511
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials., PMID:38750034
Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study., PMID:38701823
Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings., PMID:38691317
Targeting AQP9 enhanced the anti-TNF therapy response in Crohn's disease by inhibiting LPA-hippo pathway., PMID:38583685
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better., PMID:38576462
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES., PMID:38501249
Treatment with lysophosphatidic acid improves glomerulonephritis through the suppression of macrophage activation in a murine model of systemic lupus erythematosus., PMID:38436267
Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary., PMID:38414008
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups., PMID:38375817
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial., PMID:38346853
Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis., PMID:38336118
The impacts of biologic treatment on metabolic profiling in psoriasis., PMID:38284208
Lipid profile and NT-proBNP changes from pre-clinical to established rheumatoid arthritis: A 12 years follow-up explorative study., PMID:38161051
Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18-60 and 60+ Age Cohorts., PMID:37766235
Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models., PMID:37550785
Current Management and Future Perspectives in the Treatment of Lp(a) with a Focus on the Prevention of Cardiovascular Diseases., PMID:37513831
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention., PMID:37486464
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results., PMID:37390764
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer., PMID:37355629
Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials., PMID:37335067
For research use only. Not for human or drug use.
